Longeveron
LGVNLGVN · Stock Price
Historical price data
Overview
Longeveron Inc. is a Miami-based biotech focused on developing regenerative cellular therapies to improve healthspan by targeting chronic, aging-related diseases and life-threatening conditions. Its core achievement is the advancement of laromestrocel (Lomecel-B™), an allogeneic MSC therapy, into late-stage trials for Hypoplastic Left Heart Syndrome (HLHS) and Alzheimer's disease, supported by key regulatory designations like RMAT and Fast Track. The company's strategy leverages a vertically integrated manufacturing platform and pursues high-unmet-need indications with a multi-modal therapeutic hypothesis, aiming for near-term pivotal data in 2026 to drive potential BLA submissions.
Technology Platform
Platform based on culture-expanded, allogeneic Medicinal Signaling Cells (MSCs) sourced from young adult donor bone marrow, designed to exert multi-modal therapeutic effects through immunomodulation, paracrine signaling, angiogenesis, and tissue repair.
Pipeline
10| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Allogeneic MSC | Mild Alzheimer's Disease | Phase 2 | |
| Longeveron Mesenchymal Stem Cells (LMSCs) | Aging Frailty | Phase 2 | |
| Lomecel-B medicinal signaling cells | Hypoplastic Left Heart Syndrome | Phase 2 | |
| Peripheral Intravenous (IV) infusion of LMSCs | Metabolic Disease | Phase 2 | |
| Longeveron Mesenchymal Stem Cells | HLHS | Phase 1/2 |
Opportunities
Risk Factors
Competitive Landscape
In HLHS, competes primarily against standard surgical care with a unique regenerative approach. In Alzheimer's, faces intense competition from large pharma's antibody therapies but offers a mechanistically distinct cell-based strategy targeting inflammation and repair.
